Actinium Pharmaceuticals Inc (7AY1)

Currency in EUR
1.43
+0.04(+3.03%)
Delayed Data·
7AY1 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1.361.43
52 wk Range
1.005.68
Key Statistics
Bid/Ask
1.36 / 1.43
Prev. Close
1.39
Open
1.36
Day's Range
1.36-1.43
52 wk Range
1-5.68
Volume
873
Average Volume (3m)
6.85K
1-Year Change
-76.06%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
7AY1 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Currently not supported.
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy

Actinium Pharmaceuticals Inc Company Profile

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company advances two clinical stage product candidates, Actimab-A, to treat patients with myeloid malignancies including acute myeloid leukemia and myelodysplastic syndromes; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T for various blood cancer indications and gene therapies for non-malignant hematologic disorders such as sickle cell disease. It also develops ATNM-400, a preclinical non-prostate specific-membrane antigen targeting radiotherapy utilizing the Actinium-225 radioisotope for patients with prostate cancer. In addition, the company's Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). Further, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies, and its research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company is based in New York, New York.

Compare 7AY1 to Peers and Sector

Metrics to compare
7AY1
Peers
Sector
Relationship
P/E Ratio
0.0x−3.4x−0.5x
PEG Ratio
0.000.010.00
Price/Book
0.0x2.6x2.6x
Price / LTM Sales
0.0x10.1x3.3x
Upside (Analyst Target)
0.0%197.5%45.1%
Fair Value Upside
Unlock6.1%7.4%Unlock

Earnings

Latest Release
-
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

7AY1 Income Statement

People Also Watch

1.930
OTLK
-1.53%
63.69
MP
+3.56%
71.49
OKLO
-6.66%
44.430
SMR
-11.51%
8.850
UUUU
-2.64%

FAQ

What Stock Exchange Does Actinium Pharmaceuticals Inc Trade On?

Actinium Pharmaceuticals Inc is listed and trades on the Frankfurt Stock Exchange stock exchange.

What Is the Stock Symbol for Actinium Pharmaceuticals Inc?

The stock symbol for Actinium Pharmaceuticals Inc is "7AY1."

What Is the Actinium Pharmaceuticals Inc Market Cap?

As of today, Actinium Pharmaceuticals Inc market cap is 43.38M.

What Is Actinium Pharmaceuticals Inc's Earnings Per Share (TTM)?

The Actinium Pharmaceuticals Inc EPS (TTM) is 0.00.

From a Technical Analysis Perspective, Is 7AY1 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Actinium Pharmaceuticals Inc Stock Split?

Actinium Pharmaceuticals Inc has split 0 times.

What is the current trading status of Actinium Pharmaceuticals Inc (7AY1)?

As of 04 Aug 2025, Actinium Pharmaceuticals Inc (7AY1) is trading at a price of 1.43, with a previous close of 1.39. The stock has fluctuated within a day range of 1.36 to 1.43, while its 52-week range spans from 1.00 to 5.68.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.